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Introduction: Accurate, individualized prognostication for lung can-
cer patients requires the integration of standard patient and pathologic 
factors, biological, genetic, and other molecular characteristics of the 
tumor. Clinical prognostic tools aim to aggregate information on an 
individual patient to predict disease outcomes such as overall survival, 
but little is known about their clinical utility and accuracy in lung cancer.
Methods: A systematic search of the scientiﬁc literature for clinical 
prognostic tools in lung cancer published from January 1, 1996 to 
January 27, 2015 was performed. In addition, web-based resources 
were searched. A priori criteria determined by the Molecular 
Modellers Working Group of the American Joint Committee on 
Cancer were used to investigate the quality and usefulness of 
tools. Criteria included clinical presentation, model development 
approaches, validation strategies, and performance metrics.
Results: Thirty-two prognostic tools were identiﬁed. Patients with 
metastases were the most frequently considered population in non–
small-cell lung cancer. All tools for small-cell lung cancer covered 
that entire patient population. Included prognostic factors varied con-
siderably across tools. Internal validity was not formally evaluated 
for most tools and only 11 were evaluated for external validity. Two 
key considerations were highlighted for tool development: identiﬁ-
cation of an explicit purpose related to a relevant clinical popula-
tion and clear decision points and prioritized inclusion of established 
prognostic factors over emerging factors.
Conclusions: Prognostic tools will contribute more meaningfully 
to the practice of personalized medicine if better study design and 
analysis approaches are used in their development and validation.
Key Words: Lung cancer, Prognosis, Clinical prediction tools, 
Prediction models, Prognostic model.
(J Thorac Oncol. 2015;10: 1576–1589)
Anatomical stage as classiﬁed by the Tumor Node Metastasis (TNM) system is considered the predominant 
prognostic factor in lung cancer.1–3 However, the purpose of a 
staging system is to classify anatomical extent of disease, and 
in isolation, it is not sufﬁcient for accurate survival probability 
prediction.1,2,4–6 A wide variety of other prognostic informa-
tion exists, including biological, genetic, and other molecu-
lar characteristics of the tumor and standard clinical and 
pathologic factors. These factors can be considered alongside 
TNM,7–9 to reﬁne prognosis. For example, age, gender, perfor-
mance status, and tumor histology are established prognostic 
factors in lung cancer.2,6
Prognostic information arising from clinical, pathologic, 
and molecular data can be combined with (or without) the 
TNM classiﬁcation to create prognostic risk scores or groups.4 
If developed and properly validated, these tools can help clini-
cians provide a more accurate estimate of prognosis for the 
individual patient, as well as facilitate clinical decision mak-
ing including primary and adjuvant disease management.10,11
Little is known about the accuracy or clinical usefulness 
of available prognostic tools in lung cancer. The Molecular 
Modellers Working Group (MMWG) of the American Joint 
Committee on Cancer (AJCC) was charged with understand-
ing how to use information beyond stage to more accurately 
predict prognosis and thereby better guide personalized patient 
management. The MMWG identiﬁed the need to review cur-
rently available clinical prognostic tools in lung and four other 
cancers as their ﬁrst task. The initial ﬁndings were presented 
at the American Society for Clinical Oncology in 2013.12 This 
article reports on the MMWGs’ ﬁndings in lung cancer.
MATERIALS AND METHODS
The MMWG was a collaboration of surgeons, medical 
oncologists, pathologists, computational scientists, epidemi-
ologists, and biostatisticians with expertise in clinical and 
molecular model development working within the AJCC. It 
has since become two core groups (Precision Medicine Core 
and Evidence Based Medicine and Statistics Core) preparing 
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for the 8th edition of the TNM staging classiﬁcation sys-
tem.13 As a ﬁrst step, the MMWG called for the investigation 
of current clinical prognostic tools for their potential to reli-
ably predict survival outcome based on aggregate prognostic 
information.12 A focus on survival prognostication was chosen 
because of its overarching importance and because it has tra-
ditionally been used in the assessment of the prognostic value 
of TNM stage. The quality and clinical relevance of clinical 
prognostic tools were studied across ﬁve cancer sites (breast, 
colorectal, lung, melanoma, and prostate). The results of the 
lung cancer study are reported here.
Systematic Literature Review and Search 
of the Web-Based Scientific Community
The search for prognostic tools and information on 
their development and validation was performed through 
three mechanisms: a search of the peer-reviewed published 
literature (which included a systematic literature review and 
cited reference search), a search of the web-based scientiﬁc 
community, and contacting tool developers for further infor-
mation about development of publicly available web-based 
tools. Prognostic tools were deﬁned as any nomogram, risk 
classiﬁcation system, equation, risk score, electronic calcu-
lator, or other statistical regression model-based tool devel-
oped with the purpose of predicting time to death for use in 
clinical practice.10 Prognostic tools in this article include those 
developed to estimate the probability of survival at a particu-
lar point along the disease trajectory (e.g., at diagnosis, after 
treatment) or for the purpose of using a survival probability 
to inform treatment decision making. Loosely speaking, there 
is some form of statistical model underlying most prognostic 
tools, and we will use the terms prognostic tool and prognostic 
model interchangeably in many of the discussions here. The 
two main types of lung cancer, non–small-cell and small-cell 
histology, were considered separately.
The search strategy was executed in Medline, Embase, 
and HealthStar to cover the period from January 1, 1996 to 
January 27, 2015. Medical Subject Headings (MeSH) do not 
exist for prognostic tools, and so a combination of alternate 
MESH headings and key words were used after consultation 
with a health sciences librarian. An example of the search strat-
egy used for the Ovid Medline database is provided in Figure 1. 
Similar searches were conducted for the other databases using 
the appropriate syntax. Tools that may have been originally 
developed outside the literature search timeframe but that were 
identiﬁed in validation articles were considered clinically rel-
evant and included. Seemingly eligible studies were excluded 
if they met any of the following a priori exclusion criteria: 
(1) assessment of the prognostic impact of a single factor 
(unless it was updating the accuracy of an existing prog-
nostic tool); (2) inappropriate analytic purpose (e.g., multi-
variate modeling not aimed at prognostication, development 
of novel statistical methods); (3) not speciﬁc to lung cancer 
patients; (4) not original data/research (e.g., editorial, review); 
or (5) the outcome was not survival. Eligible survival end-
points included all time to death analyses (e.g., overall sur-
vival and cause-speciﬁc survival), and vital status analyses 
(e.g., probability of being dead 5 years after diagnosis). The 
search strategy was not developed to identify studies develop-
ing genomic classiﬁers built entirely on gene expression data. 
These studies were excluded.
Citations were assessed for inclusion by a single 
reviewer (A.M.), ﬁrst through their titles and abstracts and 
then as full articles. Early on, a random sample of 20 citations 
was independently reevaluated by a blinded second reviewer 
(P.G.), and the results were compared. Percent agreement was 
calculated to estimate interrater reliability. Percent agreement 
was high (>95%), and any differences identiﬁed in this exer-
cise were discussed and resolved through consensus. On the 
basics of these ﬁndings, it was judged that the rules for inclu-
sion and exclusion were being applied consistently, and we 
proceeded to screen the larger group of eligible studies.
A cited reference search of eligible articles was con-
ducted using Web of Science to identify other articles not 
found using the original search strategy. We also performed 
an on-line search for web-based clinical prognostic tools, 
both those identiﬁed through the primary literature search and 
those that were purely web-based. The search was performed 
using Google and search terms included: “clinical prediction 
tool cancer,” “online calculator cancer,” and “nomogram can-
cer.” Tool developers and/or the developer’s institution were 
contacted if there were no peer-reviewed publications or tech-
nical documents available describing the tool’s development 
process. A standard e-mail and information query form was 
sent to these contacts through the auspices of the AJCC.
Data Abstraction
We developed a list of critical criteria for the adequate 
development and validation of clinical prognostic tools. 
The list was based on the work of Harrell et al.,14,15 guide-
lines provided by Bouwmeester et al.,16 a textbook on clini-
cal prediction model development and validation,10 and on the 
REMARK reporting guidelines.17 Successive drafts of the list 
were vetted by members of the MMWG and informed by dis-
cussion at the MMWG face to face meetings in 2009, 2010, 
and 2012. The ﬁnal criteria are provided in Supplementary 
FIGURE 1. Example of the systematic literature search 
strategies used to identify clinical prognostic tools and articles 
evaluating their validation in lung cancer.
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Table (Supplemental Digital Content, http://links.lww.com/
JTO/A891). At the time that the list was developed, transparent 
reporting of a multivariable prediction model for individual 
prognosis or diagnosis, a reporting guideline for clinical pre-
diction tools,18,19 and the Critical Appraisal and Data Extraction 
for Systematic Reviews of Prediction Modelling Studies 
(CHARM) checklist,20 a reporting guideline for the systematic 
review of clinical prediction tools, had not been published. 
The list created by the MMWG includes all key criteria iden-
tiﬁed in both guidelines. Some of the criteria were common 
to both development and validation studies including study 
descriptors (e.g., authors, location, and purpose), design, 
population characteristics, outcome measurement, standard 
clinical and pathology variables, and laboratory assay-based 
measurements. Information speciﬁc to tool development 
included candidate variables for the prognostic tool, selec-
tion of candidate variables, statistical modeling methodology, 
number of events, how missing data were handled, and a list 
of the ﬁnal variables in the model. Information on internal 
validity and external validity assessments included the type of 
internal validation (e.g., apparent, cross-validation, bootstrap-
ping), type of external validation (e.g., geographic, temporal, 
independent), and measures of internal and external validity 
(e.g., overall measures of model ﬁt [e.g., Brier score], sur-
vival curves, calibration [e.g., calibration plot], discrimination 
[e.g., Harrell’s c-index]). Deﬁnitions for the key terms evalu-
ated are provided in Box 1. The assessment of clinical useful-
ness included consideration of the clinical population targeted 
by the clinical prediction tool, face validity, the purpose of 
the tool, and its practicality. Clinical relevance was deﬁned 
as those additional tool attributes outside the scope of devel-
opment and validation methodology that were important for 
consideration. The criteria in this category informed the prac-
ticality and appropriateness of using the tool in a clinical set-
ting. Clinical relevance was informally assessed by evaluating 
the choice of eligible and ﬁnal prognostic factors, the clini-
cal population addressed, the purpose and clinical question or 
decision-point targeted, and the format of the prognostic tool 
(e.g., was it available on-line? and was the equation available 
for use in the clinic?).
Summary of Data Quality
We report descriptive statistics on the development and 
validation of the eligible prognostic tools. We deﬁned formal 
statistical evaluation of internal or external validity as the 
assessment of the tool’s calibration and/or discriminative abil-
ity, which have been established as the best means of evaluat-
ing a prognostic model.10 We also tracked whether tools were 
assessed through a comparison of survival time distributions 
across prognostic groups. This approach provides evidence 
BOX 1. Definitions of Key Terms Used in Developing and Validating Prognostic Models10,69
Term Definition
Model performance Model performance refers to the ability of the underlying statistical model or algorithm to predict the outcome of interest 
(e.g., overall survival). Two important aspects of performance are calibration and discrimination. Performance should be 
evaluated both during the model development process to assess internal validity and in an external population to assess 
external validity. A prognostic tool that does not have evidence of both internal and external validity cannot be relied upon 
for accurate estimation of individualized prognosis.
Internal validity In prognostic modeling, internal validity is assessed by testing model performance during tool development, using the same 
sample of patients. This quantiﬁes the consistency of the model within the study sample.
Types of internal validation measurement methods:
• Apparent validation: using the same sample that the model was developed in.
• Split sample: randomly splitting the sample in half at the beginning of the study, using half of the population to develop the 
model and measuring the model performance in the other half.
• Cross-validation: consecutively in a random part of the sample, with model development in other parts (e.g., 10-fold: sample 
split into parts, model is developed in 9 of 10 and validated in the remaining 1 of 10; this process is repeated until all subsets 
have validated the model).
• Bootstrap: uses multiple samples drawn with replacement from the original full sample. Model is developed on the selected 
subsample and evaluated on the corresponding nonselected subsample. Performance estimates from the multiple iterations of 
the subsampling process are averaged to give an overall measure of performance for the model.
External validation In prognostic modeling, external validity is assessed by testing the model performance in plausibly similar samples of patients 
that did not contribute to the development data. This may be measured in a population from a different geographic area 
(geographic external validation); in a different time period from model development (temporal validation) or both. This may 
also be done independently by a research group with no afﬁliation to the tool developers (fully independent validation).
Calibration Calibration is a measure of agreement between the outcomes observed in the data for individual patients, with the outcome 
values predicted for individual patients by the statistical model. For prognostic tools of time to event outcomes, this is 
typically measured at a particular time point. A number of different methods may be used to evaluate calibration of a 
prognostic tool; however, the most common is a calibration plot (apparent calibration). A calibration graph plots the 
predictions of the model on the x-axis and the observed outcomes on the y-axis. Graphical presentation of calibration, 
assessed visually is a common form of evaluation for prognostic tools. For other methods of evaluating calibration, see the 
work of Steyerberg10 and Steyerberg et al.69
Discrimination Discrimination is a measure of how well a model can discern between individuals with and without the outcome or event. In 
prognostic tools, it is more often a measure of how well the model can rank a pair of individuals such that the individual 
predicted to survive longer is the individual who actually survived longer. Typically, this is measured using Harrell’s overall c 
statistic. For other methods of evaluating discrimination, see the work of Steyerberg10 and Steyerberg et al.69
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that the prognostic tool creates monotonically increasing risk 
groups and is the same approach that is often used to evaluate 
the prognostic ability of TNM stage,21 but it is not a replace-
ment for measures of calibration and/or discrimination.
RESULTS
Literature Search Results
Figure 2 outlines the published literature and web search. 
Overall, we identiﬁed 33 articles or technical documents22–54 
that supported the development of 32 clinical prognostic 
tools,22–49 with three additional articles reporting only exter-
nal validations,50–52 one focused on assessing the incremental 
value of updating an existing prognostic tool with a new piece 
of information,53 and another reported on comparing the prog-
nostic accuracy of an existing, validated tool to the prognostic 
accuracy of a radiation oncologist.54 Twenty-ﬁve tools were 
directed at prognosis in non–small-cell lung cancer (NSCLC) 
and seven in small-cell lung cancer (SCLC) (Fig. 2).
Tables 1 and 2 document key information abstracted 
on each tool. Sixteen tools were developed to predict overall 
survival, two for lung cancer-speciﬁc survival, two for vital 
status (alive at 2 years), and one for cumulative survival. 
The endpoint for the survival analysis (e.g., death from any 
cause and death from cancer) was not speciﬁed in 11 tools. 
An index date to measure survival time (e.g., from the time 
of diagnosis) was not provided for 17 of 32 tools. Four tools 
predicted survival from the time of diagnosis, eight predicted 
survival from the start of a particular treatment, and one from 
the time of recurrence. Nineteen of the tools were developed 
to deﬁne risk categories, providing the least precise estimate 
of prognosis for an individual patient but potentially inform-
ing key decision points based on risk assessment. Four tools 
were available for use on the Internet, and of those, two were 
not associated with a peer-reviewed article describing its 
development (Fig. 3). Tool development occurred primarily 
in the United States (8 of 32), China (4 of 32), South Korea 
(3 of 32), the United Kingdom (3 of 32), the Netherlands (3 
of 32), and Spain (3 of 32).
Tool Development Methods
None of the tools were developed from data prospec-
tively collected speciﬁcally for the purpose of creating a 
prognostic tool (Table 3). Nine tools used prospective data 
gathered for other purposes: seven used data collected for one 
or more randomized controlled trials and two used data aimed 
at investigating individual prognostic factors. Time period of 
data collection ranged from 1969 through 2013, with 23 tools 
(72%) developed using data collected on patients diagnosed 
10 or more years ago.
Table 3 documents that the rationale for prognostic vari-
able selection was not provided for 18 of the 32 tools. Eight 
reported that literature-based reasoning and/or clinical rel-
evance influenced variable choice and two reported choos-
ing variables from those that were conveniently available. 
Four chose variables based on statistical associations with the 
outcome based on univariate analysis. Variable measurement 
methods were rarely described, and operational deﬁnitions 
were rarely provided.
Table 3 also provides details on model development, 
including the choice of statistical approach for tool develop-
ment and how continuous variables and missing data were 
handled. Twenty-six of the 32 tools were built using the Cox 
proportional hazards model for time to event outcomes, 
two used recursive partitioning, two used support vector 
machines, and one was built using regression tree methods. 
In 19 tools, continuous prognostic factors were categorized 
before inclusion in the tool (e.g., abnormal versus normal 
laboratory values) for the purpose of creating risk groups. 
Information on the handling of missing data was not pro-
vided for 20 of 32 tools (63%). For seven tools (22%), 
patients with any missing data were excluded completely 
from the analysis. This approach is known as a “complete 
case analysis” and can lead to inaccurate predictions of the 
outcome.10,18,19
Populations and Prognostic Factors NSCLC
In NSCLC, the most often addressed population was 
advanced or metastatic disease (16 of 25) (Fig. 4, Table 4). 
The remaining NSCLC tools targeted patients with all 
stages of disease (n = 1), patients treated with curative intent 
(n = 2), or patients with stage I, II, or IIIa disease 
FIGURE 2. Results of the search for clinical prognostic tools 
and their validation articles in lung cancer.
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(n = 6). Key time points in lung cancer where prognostic 
tools could be beneﬁcial include decision making to undergo 
deﬁnitive, inductive, or adjuvant treatment or palliative man-
agement and at the time of recurrence or disease progression. 
Baseline prognosis was estimated across all stage categories. 
Prognostic tools designed for patients with operable tumors 
often aimed to identify high-risk patients who would beneﬁt 
from adjuvant therapy. The purpose of most tools in metastatic 
populations was to help physicians and patients make palliative 
management decisions by reﬁning prognosis. The probability 
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FIGURE 3. The identification of tools related to survival 
outcomes accessing both the scientific literature and the 
web-based resources
TABLE 3 A Description of Quality Criteria of Prognostic Tools 
Targeting Prognosis for Patients with Lung Cancer (n = 32)
Quality Criteria N (%)
Prognostic factor selection method
  Literature-based/clinical reasoning 8 (25)
  Screened using univariate analysis 4 (13)
  Available in existing data set 2 (6)
  Not reported 18 (56)
Missing data methods
  Complete case analysis 7 (22)
  Imputation 3 (9)
  Missing value indicator/unknown category 1 (3)
  Input favorable value for missing variables 1 (3)
  Not reported 20 (63)
Handling of continuous predictors
  Continuous 5 (16)
  Dichotomized/categorized 19 (59)
  Not reported 8 (25)
Analytic model used
  Cox proportional hazards regression 26 (81)
  Recursive partitioning 2 (6)
  Support vector machines 2 (6)
  Regression tree 1 (3)
  Method not speciﬁed 1 (3)
  Statistical model assumptions checked 5 (16)
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of survival estimated by many tools was used to inform par-
ticular treatment decisions, including whether or not to offer 
second-line chemotherapy and to identify high-risk patients 
who may be considered for treatment with erlotinib.
There was considerable heterogeneity in the selection 
of prognostic factor in the tools that were reviewed; they 
contained many emerging factors, and there was incom-
plete coverage of some established factors. In stages I to III 
NSCLC, many tools included less established prognostic 
factors that are expensive or difﬁcult to measure, whereas, 
at the same time, basic pathologic features with proven 
prognostic impact that can be easily determined in the 
resected specimens were missing. For example, the TNM 
optional factors such as vascular invasion, lymphovascu-
lar permeability, and perineural invasion are considered 
established pieces of prognostic information for resected 
NSCLC,3,55 but none of the tools included this informa-
tion. Figure 4 describes the 16 metastatic tools, showing 
that 22 prognostic factors were common to at least 2 of the 
16 tools. None of these prognostic factors were included 
across all 16 tools; however, when the target population 
deﬁnition ensures no heterogeneity of a speciﬁc prognostic 
factor (e.g., stage IV M1 population and no heterogene-
ity on the prognostic factor TNM stage), then it could be 
appropriate for this variable to be absent from the prognos-
tic tool. Performance status was the most often included 
prognostic factor, incorporated in 10 tools. Thirty-three 
additional prognostic factors were included in only one of 
each of the 16 tools (Table 4).
Populations and Prognostic Factors SCLC
In SCLC, all seven clinical prognostic tools were devel-
oped for use in the general SCLC population to reﬁne progno-
sis at the time of diagnosis (Fig. 5, Table 4). None targeted a 
particular subpopulation or time point that may have beneﬁtted 
from a tool because of medical decision-making uncertainty. 
These seven tools were developed using 14 different prognos-
tic factors. Figure 5 shows that performance status and stage 
were common to seven and ﬁve tools, respectively, and four 
other factors were common to at least two tools. Table 4 lists 
eight other factors that were included in only one tool.
Internal Validity
Twenty-eight tool development articles included evalua-
tions of internal validity, but 18 of these used 100% of the data 
that were used to develop the model (which is deﬁned as “appar-
ent” internal validation) and four randomly split their sample 
(Table 5). The use of “apparent” internal validation techniques 
lead to overly optimistic performance estimates.10 Three internal 
validation analyses used cross-validation, and three used boot-
strapping, both of which are more appropriate established meth-
ods.18,19 Cross-validation iteratively splits the original sample into 
training (for model development) and testing (for model valida-
tion) sets to estimate performance of the tool. Bootstrapping fol-
lows a similar process but deﬁnes the training set by drawing data 
with replacement from the full data set (same data can be rep-
resented more than once in the training set). Sixteen of these 28 
internal validations did not measure or report calibration or dis-
crimination of the model, but instead purported to assess validity 
FIGURE 4. Predictors used in more than one clinical prognostic tool for survival in advanced/incurable non–small-cell lung 
cancer (n = 12 tools). See Table 4 for predictors used in only one tool.
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by establishing that there was a statistically signiﬁcant differ-
ence in survival time distribution between risk groups deﬁned 
by the prognostic tool. A Brier score was used to measure model 
performance in one tool, ranging from 0.119 to 0.162 across 
subgroups (smaller is better). Performance of four prognostic 
tools was assessed using an R2 statistics, a measure of variation 
in the outcome predicted by the tool, with all values being less 
than 0.31. Calibration was evaluated in the development of three 
tools, two with results provided as graphs of predicted versus 
observed survival (calibration plots). Discrimination was evalu-
ated in 12 tools with concordance statistic that ranged from 0.64 
to 0.83. No temporal trends in the inclusion of an internal valida-
tion assessment were noted.
External Validity
The majority of prognostic tools (21 of 32) were not 
evaluated in an independent sample that was used for tool 
development (external validation) (Table 5). Ten articles per-
formed 17 assessments of the external validity of 11 tools. Of 
the 11 tools with evidence of external validation, three were 
evaluated by reporting the statistical signiﬁcance of the separa-
tion of survival curves by risk strata with no formal measures 
of calibration, discrimination, or other valid ways of assessing 
predictive ability reported. Four tools were evaluated using 
Brier score (0.071–0.163) or R2 (0.08–0.343). Calibration was 
assessed in two tools, one through a calibration plot and one 
through the informal comparison of predicted versus observed 
survival probabilities. Five tools were evaluated for their dis-
crimination ability; concordance statistics ranged from 0.687 
to 0.76. de Jong et al.24 evaluated the ability of three different 
tools to distinguish between two patients with better or worse 
prognosis but did not formally calculate a concordance statis-
tics. No trends in the performance of external validations were 
noted over time.
DISCUSSION
This study described the clinical prognostic tool land-
scape in lung cancer. We identiﬁed 32 clinical prognostic tools 
from the peer-reviewed literature and web-based resources. 
Metastatic disease was the most often considered clinical 
population in NSCLC, and all tools in SCLC were intended 
for the entire population of patients with SCLC. There was 
signiﬁcant heterogeneity in the prognostic factors included. 
Most tool developers did not conduct a formal evaluation 
of the internal validity of the underlying statistical model. 
Nine tools were evaluated for external validity, with varying 
degrees of rigor.
This study supports conclusions of previous investiga-
tions regarding the methodological quality of clinical predic-
tion tools in other clinical settings: the methodology used to 
develop and validate many tools is poor, with little reliable 
external generalizability or attention to the impact these tools 
have on clinical decision making and patient outcomes.11,16,56–63 
The accuracy of the tools’ predictions was generally insuf-
ﬁcient to use them to justify deviating from standard clini-
cal decisions. These ﬁndings provide further emphasis to the 
widespread recognition that methodological improvements 
are required to optimize clinical prediction tools for patient 
care.11,16,19,58–63 Excellent guidance on best practices for the 
conduct of prognostic research, tool development, and prog-
nostic study reporting has been published.16,19,56–61 More lead-
ership in the promotion of these methodological requirements 
to tool developers, tool resources and scientiﬁc journals is 
badly needed.
Previous reviews of clinical prediction tool method-
ology have not speciﬁcally evaluated lung cancer prognos-
tic tools to gain a clinically relevant understanding of their 
particular strengths and weaknesses. This review identiﬁed 
that improvement in the development, validation, and use of 
prognostic tools for survival in patient with lung cancer will 
require addressing the choice of relevant clinical populations 
and clinical management decision points and the signiﬁcant 
TABLE 4. Predictors Included in Only One Tool in Predicting 
Survival for Patients with Incurable/Metastatic NSCLC (n = 9 
Tools) and SCLC (n = 7 Tools)
NSCLC SCLC
No. of metastatic sites Bicarbonate
Adrenal metastases White blood cell count
Alcohol consumption Platelet count
Bevacizumab Age
Bone metastasis CYFRA 21-1
Brain metastases Neutrophils
BUN Liver scan results
CA125 Alanine transaminase
Calcium Feinstein symptom score
Chemotherapy
CRP
Ethnicity
Feinstein symptom score
INR
Intra-abdominal metastasis
Liver metastasis
Loss of appetite
Mediastinal nodes
N/L ratio
Number of prior regimens
Objective response to ﬁrst line
Progression-free interval during previous 
chemotherapy
Protein
Response to prior treatment
Skin metastasis
Subcutaneous metastasis
Surgery
Time from diagnosis to geﬁtinib therapy
Time from ﬁrst-line chemotherapy
Total serum bilirubin
Total triglycerides
Tumor size
Type of ﬁrst-line therapy
BUN, blood urea nitrogen; CRP, C-reactive protein; INR, International Normalized 
ratio; N/L, neutrophil count/lymphocyte count ratio; NSCLC, non–small-cell lung 
cancer; SCLC, small-cell lung cancer.
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heterogeneity in the consideration and inclusion of prognostic 
factors. This targeted information is necessary to build on the 
methodological ﬁndings of this review and guide future direc-
tions in clinical prognostic tool development and implementa-
tion in lung cancer patients.
In addition to prognostication at diagnosis, multiple 
prognostic judgments within subpopulations are also neces-
sary as the disease progresses (or regresses), both to reestimate 
prognosis and help to inform treatment decisions. This review 
identiﬁed that none of the tools developed for use in SCLC 
were targeted to a particular clinical management decision 
point. Similarly, many in NSCLC were targeted to reﬁning 
prognosis at the time of diagnosis. Stage-speciﬁc prognostica-
tion at diagnosis for SCLC and NSCLC could be improved by 
the combination of clinical, pathological, and biological fac-
tors. For example, for a T1aN0M0 NSCLC patient, the addi-
tion of pathological factors (perineural invasion,64 vascular 
invasion,65 or lymphatic permeation66) and established clinical 
factors (age and performance status) may alter their prognosis 
at diagnosis from relatively good to much worse.
We also propose that successive prognostic tools are 
needed along the disease trajectory. None of the prognostic 
tools in SCLC targeted any particular clinical management 
decision, whereas tools in NSCLC were designed for multiple 
purposes. Therefore, gaps in the coverage of key clinical deci-
sion points exist. Such individualized prognostication across 
the trajectory could provide information that a patient and 
their family may want for planning and has the potential to 
better inform management decisions. For example, before any 
surgical treatment has been done, postoperative 5-year sur-
vival based on TNM stage alone for an individual patient may 
be 90%. In the same patient, a postoperative prognostic tool 
that included the pathological TNM, the deﬁnitive histopatho-
logical type, and EGFR mutation status, for example, would 
modify the prognostic assessment of the disease. The tool may 
drop that individual’s personal estimate to 40%, and the deci-
sion to move forward with surgery may change based on this 
more personalized prognosis.
Consistency and a balance between the practical and the 
ideal are needed when identifying relevant prognostic factors 
for inclusion in prognostic tools for lung cancer, regardless of 
the clinical population addressed or the decision-point targeted. 
There was substantial heterogeneity in prognostic factor choices 
in the tools we reviewed, even within similar clinical presenta-
tions. Tools also contained many emerging factors; the coverage 
of some established factors was not in evidence, and many of 
the tools included expensive, difﬁcult to measure factors that 
are not reliably or routinely collected. Although the number of 
FIGURE 5. Predictors used in more than one clini-
cal prognostic tool for survival small-cell lung cancer 
(any stage) (n = 7 tools). See Table 4 for predictors 
used in only one tool.
TABLE 5. Details of Tool Performance Evaluations
Performance Measure
Internal  
Validation 
(n = 28)
External  
Validation 
(n = 11)
Internal validation method
  Apparent 18 (64) —
  Cross-validation 3 (11) —
  Split sample 4 (14) —
  Bootstrapping 3 (11) —
External validation method
  Independenta — 5 (45)
Overall model performanceb
  Brier score 1 (4) 1 (9)
  R2 3 (11) 4 (36)
Calibration
  Graph (plot/intercept/slope) 2 (7) 1 (9)
  Other 1 (4) 1 (9)
Discrimination
  C-statisticsc 9 (32) 2 (18)
  Other 1 (4) 3 (27)
Survival analysis only with signiﬁcance test 16 (57) 3 (27)
aOther approaches to external validation such as geographic validation or temporal 
validation could have been used but were not used for any of the tools reviewed (Table 6).
bBrier score and R2 could have been calculated on the same model.
cConcordance index based on Harrell’s C statistics for models using time to 
event data.
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established prognostic factors in lung cancer is small,3,55 con-
sideration of fundamental prognostic knowledge during tool 
development is vital. Large-scale, standardized data sharing 
agreements, such as that led by the IASLC,21,67,68 could better 
supply physicians and scientists with the appropriate informa-
tion needed to develop high-quality prognostic tools.
This study may underestimate the number of prognostic 
tools developed in lung cancer during the study time frame. 
The lack of standardized MESH headings for this type of 
study limited the ability to ﬁnd all relevant prognostic tools. 
For example, the study by Blanchon et al.71 was not identi-
ﬁed through the search terms used in this systematic review. 
However, we applied many methods to optimize the capture of 
prognostic tools in lung cancer, including consultation with a 
health sciences librarian for the systematic review, cited refer-
ence searches, and a search of on-line resources.
The existing clinical prognostic tool literature in lung 
cancer has both methodological flaws and clinical challenges. 
The future of prognostic tool development, validation, and use 
in patients with lung cancer must begin with the identiﬁca-
tion of a clear, clinical objective, targeting a precise decision 
point within the disease trajectory. High-quality development 
and validation methods for prognostic tools that build upon 
established prognostic information will improve the accuracy 
of individualized estimates of prognosis and provide neces-
sary credibility for their implementation into clinical practice.
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